Lantern Pharma (NASDAQ: LTRN), a pioneering biotech firm utilizing its RADR(R) AI platform to streamline the development of precision oncology drugs, has announced a strategic partnership with IBN to spearhead its corporate communications efforts. This collaboration comes at a pivotal moment as Lantern Pharma advances its clinical programs targeting a range of cancers, including lung, brain, breast, and blood cancers, with three AI-guided candidates and a subsidiary focused on central nervous system (CNS) therapies currently in active trials.
The engagement with IBN is set to amplify investor awareness around Lantern Pharma's innovative approach to oncology drug development. The company's RADR(R) platform, which integrates over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms, has significantly reduced the time and cost associated with bringing new therapies from the conceptual stage to clinical trials. On average, Lantern Pharma's drug programs have progressed from initial AI insights to first-in-human clinical trials in just 2-3 years, with an approximate cost of $2.5 million per program.
This partnership underscores the critical role of artificial intelligence in revolutionizing the oncology sector, offering hope for faster, more cost-effective development of targeted cancer treatments. For investors and the broader medical community, Lantern Pharma's progress represents a promising frontier in the fight against cancer, leveraging cutting-edge technology to address some of the most challenging aspects of drug development.
For further details on Lantern Pharma's advancements and its collaboration with IBN, interested parties can view the full press release here.
